This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons Growth Investors Will Love Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) possesses solid growth attributes, which could help it handily outperform the market.
5 Price-to-Book Value Picks for September
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.
Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Alexion Wins EC Nod for Soliris in Nervous System Disorder
by Zacks Equity Research
Alexion (ALXN) receives EC approval for the label expansion of lead drug, Soliris, for the indication of rare, devastating disorder of the central nervous system.
Top Analyst Reports for Costco, PayPal & NextEra
by Mark Vickery
Today's Research Daily features updated research reports on 16 major stocks, including Costco (COST), PayPal (PYPL) and NextEra (NEE).
Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene
by Zacks Equity Research
Alexion's (ALXN) shares dip after gaining steam on rumors of a potential acquisition by Amgen last week.
ALXN vs. CBM: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Gilead & Galapagos Close Research & Development Agreement
by Zacks Equity Research
Gilead (GILD) closes collaboration agreement with Galapagos, per which the latter will receive an upfront license fee payment of $3.95 billion.
Why Is Alexion (ALXN) Up 4.6% Since Last Earnings Report?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5%
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
by Zacks Equity Research
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
NuCana Stops Patient Enrollment in Pancreatic Cancer Study
by Zacks Equity Research
NuCana (NCNA) suspends patient enrollment in the phase III study on Acelarin, currently evaluated for treating patients with metastatic pancreatic cancer, who were unfit for combination chemotherapy.
Alexion (ALXN) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Alexion (ALXN) possesses solid growth attributes, which could help it handily outperform the market.
Inovio Ends Enrollment in Anal Dysplasia Study on VGX-3100
by Zacks Equity Research
Inovio (INO) closes enrollment in the phase II study evaluating VGX-3100 for the treatment of HPV-related high-grade anal dysplasia. Shares up.
Nabriva (NBRV) Gains FDA Approval for Pneumonia Drug Xenleta
by Zacks Equity Research
The FDA approves Nabriva's (NBRV) new drug application for both intravenous and oral formulations of Xenleta to treat adult patients with community-acquired bacterial pneumonia.
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?
Amgen (AMGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Amgen (AMGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals
Can Value Investors Consider Alexion (ALXN) a Worthy Pick?
by Zacks Equity Research
Alexion (ALXN) stock may be a good choice for value-oriented investors right now from multiple angles.
Mergers & Acquisitions Take Center Stage in Biotech Industry
by Zacks Equity Research
Mergers & acquisitions are in focus in the biotech industry as it undergoes a wave of consolidation.
ALXN vs. CBM: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. CBM: Which Stock Is the Better Value Option?
Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil
by Zacks Equity Research
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.
Biotech ETFs in Focus on Impressive Q2 Earnings Results
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with wide exposure to a few biotechnological companies which released solid Q2 earnings results recently.
Looking for a Growth Stock? 3 Reasons Why Alexion (ALXN) is a Solid Choice
by Zacks Equity Research
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.